教 師 簡 歷
基本信息
照片/Photo👨🏻💼：
電子郵箱/E-mail：bxiao@yggyf.cn
個人簡介
肖波，教授、博士生導師，生物技術系主任📑。先後入選“全球頂尖前10萬科學家排名”榜單、“2020全球前2%頂尖科學家”💟、國家級青年人才計劃和重慶市委組織部“青年拔尖人才”等‼️。
課程教學
本科生課程：
《細胞生物學》、《生命科學進展》、《細胞生化及分子生物學》
研究方向及課題
口服納米醫學：基於植物（如桑葉、茶葉等）👨🏼⚖️、蠶絲蛋白（絲素、絲膠等）和合成高分子的藥用功能和特殊理🤟🏼、化性能，我們試圖利用其作為天然納米藥物或藥物（如siRNA🙇、pDNA👰、化學藥物等）的載體材料，設計並構建各種新型納米粒子、微米粒子🦨、水凝膠或纖維等載藥系統，用於多種炎症性疾病和腫瘤的診斷😶、預防和治療。近年來，以唯一通訊作者或最後一位通訊作者在Gastroenterology、ACS nano、Advanced Drug Delivery Review、Acta Pharm. Sin. B、Biomaterials🤶、Journal of Controlled Release🧵、 Theranostics、Molecular Therapy和ACS Applied Materials & Interfaces等國際頂級或權威雜誌上發表學術論文50余篇。先後主持國家高層次人才項目🦋、國家自然科學基金（3項）、重慶市自然科學基金和美國心臟協會基金等項目。
研究成果
[1] Ya Ma, Lian Duan, Jianfeng Sun, Shuangquan Gou, Fengyuan Chen, Yuqi Liang, Fangyin Dai, Bo Xiao*. Oral nanotherapeutics based on Antheraea pernyi silk fibroin for synergistic treatment of ulcerative colitis. Biomaterials 2022;282: 21410.（IF = 12.4）
[2] Shuangquan Gou, Nanxi Chen, Xiaoai Wu, Menghang Zu, Shixiong Yi, Binwu Ying*, Fangyin Dai, Bowen Ke*, Bo Xiao*. Multi-responsive nanotheranostics with enhanced tumor penetration and oxygen self-producing capacities for multimodal synergistic cancer therapy. Acta Pharm. Sin. B 2022;12(1):406-423. (IF = 11.4）
[3] Chen Q., Li Q., Liang Y., Zu M., Chen N., Canup B., Luo L., Wang C.*, Zeng L.*, and Xiao B.* Natural exosome-like nanovesicles from edible tea flowers suppress metastatic breast cancer via ROS generation and microbiota modulation. Acta Pharm. Sin. B 2022;12(2):907-923. (IF = 11.4）
[4] Menghang Zu, Dengchao Xie, Brandon S.B. Canup, Nanxi Chen, Yajun Wang, Ruxin Sun, Zhan Zhang, Yuming Fu,* Fangyin Dai,* and Bo Xiao*. ‘Green’ nanotherapeutics from tea leaves for orally targeted prevention and alleviation of colon diseases. Biomaterials 2021; 279: 121178. （IF = 12.4）
[5] Zu M., Ma Y., Cannup B., Xie D., Jung Y., Zhang J., Yang C., Gao F.*, Merlin D.*, and Xiao B.*. Oral delivery of natural active small molecules by polymeric nanoparticles for the treatment of inflammatory bowel diseases. Adv. Drug Deliv. Rev. 2021;176:113887. (IF = 15.4）
[6] Zhang X., Huang Y., Song H., Canup B.S.B., Gou S., She Z., Dai F.*, Ke B.*, and Xiao B.*. Inhibition of growth and lung metastasis of breast cancer by tumor-homing triple-bioresponsive nanotherapeutics. Journal of Controlled Release 2020;328:454-469. （IF = 9.7）
[7] Gou S., Yang J., Ma Y., Zhang X., Zu M., Kang T., Liu S., Ke B.*, and Xiao B.*. Multi-responsive nanococktails with programmable targeting capacity for imaging-guided mitochondrial phototherapy combined with chemotherapy. Journal of Controlled Release 2020;327: 371-383. （IF = 9.7）
[8] Gou S., Huang Y., Wan Y., Ma Y., Zhou X., Tong X., Huang J.*, Kang Y.*, Pan G., Dai F., and Xiao B.*. Multi-bioresponsive silk fibroin-based nanoparticles with on-demand cytoplasmic drug release capacity for CD44-targeted alleviation of ulcerative colitis. Biomaterials 2019; 212:39-54. （IF = 12.4）
[9] Xiao B.*, Laroui H., Viennois E., Ayyadurai S., Charania M.A., Zhang Y., Zhang Z., Baker M.T., Zhang B., Gewirtz A.T., and Merlin D.. Nanoparticles with surface antibody against CD98 and carrying CD98 small interfering RNA reduce colitis in mice. Gastroenterology 2014; 146(5):1289-1300.（IF = 22.6）
[10] Xiao B.*, Viennois E., Chen Q., Wang L., Han M., Zhang Y., Zhang Z., Kang Y., Wan Y., and Merlin D.. Silencing of Intestinal Glycoprotein CD98 by Orally Targeted Nanoparticles Enhances Chemosensitization of Colon Cancer. ACS nano 2018;12:5253-5265.（IF = 15.8）
